| Identification | Back Directory | [Name]
Myo-Inositol Trispyrophosphate HexasodiuM Salt | [CAS]
23103-35-7 | [Synonyms]
ITPP
ITTP HexasodiuM Salt
Myo-Inositol Tripyrphosphate HexasodiuM salt
Myo-Inositol Trispyrophosphate HexasodiuM Salt
Myo-Inositol Trispyrophosphate HexasodiuM Salt 9
MYO-INOSITOL TRISPYROPHOSPHATE HEXASODIUM (ITPP)
Inositol cyclic-1,2:3,4:5,6-tris(P,P'-dihydrogen diphosphate) hexasodium salt
Myo-Inositol Cyclic 1,2:3,4:5,6-Tris(dihydrogen pyrophosphate)) HexasodiuM Salt
Myo-Inositol Cyclic 1,2:3,4:5,6-Tris(P,P'-dihydrogen diphosphate) HexasodiuM Salt | [Molecular Formula]
C6H6Na6O21P6 | [MDL Number]
MFCD28899029 | [MOL File]
23103-35-7.mol | [Molecular Weight]
791.926 |
| Chemical Properties | Back Directory | [Melting point ]
>270°C (dec.) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under Inert Atmosphere | [solubility ]
Water (Slightly, Sonicated) | [form ]
Solid | [color ]
White to Off-White | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Chemical Properties]
Off-White Solid | [Uses]
A novel membrane-permeant allosteric effector of hemoglobin (Hb), enhances the regulated oxygen release capacity of red blood cells, thus counteracting the effects of hypoxia in diseases such as cancer and cardiovascular ailments. | [in vivo]
Non-salt dose:
myo-Inositol trispyrophosphate (1.5 g/kg; intraperitoneal injection; twice a week for 4 weeks) has a protective effect in rat model of myocardial infarction[1].
myo-Inositol trispyrophosphate (1.5 g/kg; intravenous injection; once a week for 11 weeks) has antitumor activity in a rat model of pancreatic cancer[2]. | Animal Model: | Male Wistar rats (280-320 g) with myocardial infarction[1] | | Dosage: | 1.5 g/kg (Non-salt dose) | | Administration: | Intraperitoneal injection (i.p.); twice a week for 4 weeks | | Result: | Essentially halted the increase of LV dilation and significantly reduced impairment of LV ejection fraction, while it had no effect on sham-operated rats.
|
| Animal Model: | DSL-6A/C1 tumors treated immunocompetent male Lewis rats[2] | | Dosage: | 1.5 g/kg (Non-salt dose) | | Administration: | Intravenous injection (i.v.); once a week for 11 weeks | | Result: | Significantly extended the survival time of rats.
Basically did not cause liver metastasis and primary tumor growth was restricted to 2 cm3.
Restored the pO2 pressure in tumors reducing hypoxia-inducible and proangiogenic factors. |
|
|
|